Newsfile Corp
23 May 2026, 01:33 UTC · 2h ago
Source · https://www.newsfilecorp.com/release/298656/ROSEN-A-LONGSTANDING-FIRM-Encourages-Immutep-Ltd.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-IMMP
Read source
Story key points
3 claims · impact-rated
Immutep Ltd. is facing a class action lawsuit alleging it concealed internal data suggesting the TACTI-004 trial was likely to fail its primary efficacy and safety endpoints. — Allegations of clinical trial failure and misleading disclosures are highly material for biotech companies and typically lead to significant share price declines.
-0.70The lawsuit claims that Immutep's January 2026 SEC filing falsely stated the TACTI-004 trial was exhibiting 'strong operational progress'. — Specific allegations of fraudulent SEC filings increase the risk of regulatory scrutiny and legal liabilities.
-0.40The class action period covers purchasers of Immutep ADRs between March 24, 2025, and March 12, 2026. — Defines the scope of potential legal liability and the group of affected investors, though less impactful than the clinical failure claim itself.
-0.10Impact vectors
Search tags
3 dimensions · 9 clusters
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Ticker attribution
Model heads
The company is mentioned as being subject to a securities class action lawsuit.
The company is facing a class action lawsuit alleging false and misleading statements regarding clinical trial results.
The company is mentioned as being subject to a securities class action lawsuit.
No ticker relationship head found.
